
A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo nature.com/articles/s41587-0…

#stemcells researcher | Director of Cell Processing Facility @umontpellier @CHU_Montpellier | #iPScells #lung | @stemgenomics

A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo nature.com/articles/s41587-0…

Talking about acceleration: In 13 months, the best AI agent went from completing 2.5% of real freelance projects on the Remote Labor Index to 41.3% with Claude Fable 5.2. These were paid projects that took human professionals 29 hours on average, with briefs provided and client calls excluded. So yeah, white collar work will get a wake-up in 2027.

A 37-year-old woman with 10 years of abdominal pain. —The AI makes the diagnosis and recommends a successful treatment. —The physician "diagnosed a patient with a condition I had never diagnosed before and started treatment largely on the basis of the output of a chatbot." In today's @NEJM nejm.org/doi/full/10.1056/NE…

Cease doomscrolling and start joyreading: the amazing Cecilia Cotta - with her trademark courage and creativity - leads a team at Tessera to a major advance in the field: generating stable CAR-T cells in vivo using LNP mRNA delivery - a key step towards CAR-T scalability and affordability! Gregor- and Rosalindspeed, Tessera! cell.com/cell/fulltext/S0092…

A second report (both this year) of AAV-driven insertional mutagenesis in gene therapy. Two out of ~3,000 total who received AAV. = nonzero and concerning. But VERY low. = it's all about benefit-risk, folks.
Vo and colleagues report AAV integration in a paraspinal neoplasm after gene therapy. The integrated sequence retained a CAG promoter–enhancer and activated a developmental transcription factor. Read the full report: nej.md/4jVtf6z

⚠️ AAV insertional mutagenesis is a real oncogenic risk. Novartis reports 9 tumors among >6,000 Zolgensma-treated patients. Vector integration involving the GLI1 oncogene was detected in 2 cases. A critical safety signal for long-term AAV gene therapy surveillance. #GeneTherapy

🚨 Gilead/Kite has announced a partial clinical hold on the Ph2 PALISADES-1 and Ph3 PALISADES-2 trials of KITE-753 in rDLBCL following grade 3–4 ICANS. KITE-753 is a next-generation, dual targeting (CD19 and CD20) and dual costimulation (CD28 41BB). fiercebiotech.com/biotech/gi…

It's already been 20 years since Kazutoshi Takahashi and Shinya Yamanaka published their landmark paper on iPSCs in Cell. Amazing how a single publication could spark an entire field! #iPSCell nature.com/articles/s41556-0…

Last night an AI agent performed brain surgery on a mouse. We gave it 19 gene therapy vectors in a spreadsheet, a mouse model of epilepsy, access to a motorize surgery rig with cameras and one goal: reduce seizures. It picked the drug. It picked the brain region. It derived the coordinates from three papers. Then it drove the stereotaxic arms into the brain and injected 250 nanolitres while watching the entry site through the rig camera for bleeding. A licensed vet gated every irreversible step and held a physical kill switch to stop the AI agent. Thread on what it decided, what it saw, and the moment it refused to let me override it. [Writing this on the spot out of excitement, but I've been 18hrs in front of my laptop coding and coordinating this, so keeping it brief and descriptive, more cohesive thoughts on this soon...]

'The Child' is one of three new limited-edition prints available now at tomgauld.com/shop

This is a great loss for the #DevBio community and the #SCBEM field in particular. Marta was (how hard to write this) a positive person, a creative scientist & a great collague. Will be missed.
Desaparecida en el accidente de trenes Marta Shahbazi, una de las científicas españolas más brillantes elpais.com/ciencia/2026-10-3…

The Singularity is coming for Physics and Biology. RIP Math.

VERY encouraging Phase 1 data for FT819: #iPSC-derived allogeneic #CARTcells show a promising safety profile and early signs of efficacy in lupus nephritis! Small cohorts and preliminary results, but an exciting step for off-the-shelf cell therapies. biospace.com/press-releases/…

Après des jours à dire que Parcoursup c’était une plate-forme de « matching »et que les filtres étaient définis par les universités et écoles, je découvre cette vidéo d’un prof et elle est juste parfaite. À visionner. 👇🏻👇🏻
Quel est le véritable problème avec #Parcoursup ? Un prof répond :

Our "Single-cell multi-omics in IPF & COPD: from atlas to impact" is out! We provide a brief guide to analytic approaches, an overview of how the technologies impact our understanding of the 2 diseases, limitations, future directions. A 🧵 will follow publications.ersnet.org/cont…

A first for CRISPR: powerful prime editing alters DNA directly in the human body #GeneTherapy nature.com/articles/d41586-0…